Novatek Pharmaceuticals

Novatek Pharmaceuticals

Early Stage

Development of immunomodulatory drugs

Development of immunomodulatory drugs

Overview

Funding data not publicly available
Platform

Dealmaker Securities

Start Date

01/03/2023

Close Date

04/26/2023

Min. Goal
$50,000
Max. Goal
$5,000,000
Min. Investment

$500

Security Type

Equity - Common

Series

Series A

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.00

Pre-Money Valuation

$5,000,000

Year Founded

2020

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B/B2C

Margin

Medium

Capital Intensity

High

Location

Pearland, Texas

Business Type

Growth

Novatek Pharmaceuticals, with a valuation of $5 million, is raising funds on Dealmaker Securities. It is a pharmaceutical company focused on the development of immunomodulatory drugs related to cancers and infectious diseases. The aim of Novatek Pharmaceuticals’ investigations is to develop drugs to empower naturally-derived immunotherapy and reduce the adverse effects of disease and cytotoxic therapies. Novatek Pharmaceuticals is led by an experienced team and has several products in clinical trials. Mohamed Kaseb founded Novatek Pharmaceuticals in April 2020. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5 million. The campaign proceeds will be used for marketing, research and development, manufacturing, and general working capital.

Summary Profit and Loss Statement

FY 2021 FY 2020

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$3,446,214

$1,148,011

Summary Balance Sheet

FY 2021 FY 2020

Cash

$16,640

$78,288

Accounts Receivable

$0

$0

Total Assets

$16,640

$78,288

Short-Term Debt

$2,207,386

$1,076,299

Long-Term Debt

$2,253,479

$0

Total Liabilities

$4,460,865

$1,076,299

Financials as of: 01/03/2023
Create a free account today to gain access to KingsCrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Novatek Pharmaceuticals on Dealmaker Securities 2023
Platform: Dealmaker Securities
Security Type: Equity - Common
Valuation: $5,000,000
Price per Share: $2.00

Follow company

Follow Novatek Pharmaceuticals on Dealmaker Securities 2023

Buy Novatek Pharmaceuticals's Deal Report

Warning: according to the close date for this deal, Novatek Pharmaceuticals may no longer be accepting investments.

Novatek Pharmaceuticals Deal Report

Get KingsCrowd’s comprehensive report on Novatek Pharmaceuticals including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Novatek Pharmaceuticals is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Novatek Pharmaceuticals deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge